Oncotype IQ genomic testing
Ended Awarded
- Contract number
- HT001425FE013
- Awardee
-
Genomic Health, Inc. UEI RHN3L7SBF7J6
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $145,066
Award facts
- Contract value 100% obligated
- $145,066.32 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 621511 Medical Laboratories
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Bethesda, MD 20889, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Health Agency awarded Genomic Health, Inc. a $145,066.32 firm fixed-price BPA call for Oncotype IQ genomic testing services, with an ultimate completion date of September 7, 2026. Genomic Health, a subsidiary of Exact Sciences Corporation, specializes in advanced genetic testing services focused on oncology diagnostics, particularly the Oncotype DX portfolio of gene expression assays. These tests support cancer screening, treatment selection, and disease monitoring across breast, prostate, and colon cancers. The contract was awarded without a set-aside designation and will be performed in Bethesda, Maryland, supporting the Defense Health Agency's mission to provide comprehensive healthcare services to the military population.
This award represents a delivery order under one of Genomic Health's existing Indefinite Delivery Vehicles with the Defense Health Agency, specifically a $5 million single-award Blanket Purchase Agreement for diagnostic oncology prostate testing. The company has demonstrated sustained success in providing genomic testing services to multiple federal agencies, including the Department of Veterans Affairs, Air Force, Army, and Navy medical facilities. Through its established IDVs and prior contract performance, Genomic Health has built a track record of delivering specialized cancer diagnostic services that enable healthcare providers to make informed treatment decisions based on personalized genetic analysis, supporting the federal healthcare system's commitment to precision medicine in oncology care.
Quick answers
Who was awarded contract HT001425FE013?
HT001425FE013 was awarded to Genomic Health, Inc. by Defense Health Agency (Department of Defense) on September 8, 2025.
How much is contract HT001425FE013 worth?
The government has obligated $145,066 on HT001425FE013.
Is contract HT001425FE013 an order under another contract?
Yes. HT001425FE013 is a BPA call under HT001421A0031, a blanket purchase agreement.
Was contract HT001425FE013 competed?
The extent of competition for HT001425FE013 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award